AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 129 filers reported holding AUDENTES THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $24,534,000 | +113.0% | 410,000 | 0.0% | 0.78% | +68.8% |
| Q3 2019 | $11,517,000 | -25.8% | 410,000 | 0.0% | 0.46% | -18.3% |
| Q2 2019 | $15,523,000 | -23.9% | 410,000 | -21.5% | 0.56% | -28.5% |
| Q1 2019 | $20,388,000 | +91.3% | 522,500 | +4.5% | 0.79% | +56.3% |
| Q4 2018 | $10,660,000 | -36.6% | 500,000 | +17.6% | 0.50% | -17.4% |
| Q3 2018 | $16,827,000 | +0.1% | 425,025 | -3.4% | 0.61% | -5.9% |
| Q2 2018 | $16,812,000 | -1.0% | 440,000 | -22.1% | 0.65% | -10.6% |
| Q1 2018 | $16,978,000 | +3.5% | 565,000 | +7.6% | 0.72% | -2.7% |
| Q4 2017 | $16,406,000 | +11.6% | 525,000 | 0.0% | 0.74% | +9.7% |
| Q3 2017 | $14,705,000 | +29.1% | 525,000 | -11.8% | 0.68% | +17.9% |
| Q2 2017 | $11,386,000 | +33.6% | 595,200 | +19.0% | 0.58% | +16.9% |
| Q1 2017 | $8,520,000 | -3.8% | 500,000 | +3.1% | 0.49% | -17.0% |
| Q4 2016 | $8,861,000 | +2.6% | 485,000 | 0.0% | 0.59% | +9.6% |
| Q3 2016 | $8,638,000 | – | 485,000 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEXTHERA CAPITAL LP | 294,013 | $11,131,000 | 9.27% |
| GREAT POINT PARTNERS LLC | 1,922,937 | $72,802,000,000 | 8.08% |
| Versant Venture Management, LLC | 553,916 | $20,971,260,000 | 6.11% |
| Foresite Capital Management III, LLC | 315,331 | $11,938,000 | 3.92% |
| Casdin Capital, LLC | 965,000 | $36,534,900,000 | 3.42% |
| Sofinnova Investments, Inc. | 933,640 | $35,348,000 | 3.25% |
| Opaleye Management Inc. | 280,000 | $10,601,000 | 3.23% |
| Redmile Group, LLC | 2,972,167 | $112,526,000 | 3.18% |
| PFM Health Sciences, LP | 3,228,679 | $122,238,000 | 2.32% |
| Eversept Partners, LP | 159,526 | $6,039,654 | 1.69% |